Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study

Abstract

ObjectiveTo compare the efficacy and safety of transarterial chemoembolization (TACE) combining with sorafenib or apatinib for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).MethodsFrom June 2015 to March 2020, a total of 89 consecutive advanced HCC patients with PVTT who were treated with sorafenib-TACE (S-TACE) or apatinib-TACE (A-TACE) in our center were enrolled. The overall survival (OS), time to progression (TTP), tumor response, and adverse events in the two groups were compared.ResultsThere were 32 and 41 patients included in the S-TACE group and A-TACE group, respectively. The median follow-up was 10.0 months (range, 3.0–36.0 months) in the whole study. The median OS (11.0 vs. 10.0 months, P = 0.419), median TTP (5.0 vs. 6.0 months, P = 0.073), and tumor response (P = 0.529) between the S-TACE group and the A-TACE group were not significantly different. The adverse events related to sorafenib or apatinib were tolerable.ConclusionS-TACE and A-TACE exhibited comparable prognosis for HCC patients with PVTT, which provide another effective and safe method of A-TACE for these patients except for conventional S-TACE.

Efficacy of Transarterial Chemoembolization Combined with Molecular Targeted Agents for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

“…Subsequently, 109 review articles, 102 published abstracts or conference proceedings, 128 unrelated topics, and four articles without a study endpoint (PFS or OS) were excluded. Finally, 39 cohort studies and two RCTs were included in the network meta-analysis [ 10 , 17 , 20 , 21 , 22 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 ]. The PRISMA flow diagram is presented in Supplementary Material S2 .…”

“…It remains controversial whether treatment with TACE plus apatinib prolongs the survival of patients with uHCC when compared with TACE plus sorafenib. A multicenter retrospective study revealed that TACE–apatinib yielded shorter PFS than TACE-sorafenib and no statistical difference in OS [ 21 ], whereas another study demonstrated that TACE plus sorafenib and TACE plus apatinib exhibited comparable prognosis for HCC patients with PVTT [ 20 ]. Our network meta-analysis showed that TACE plus apatinib resulted in significantly improved OS compared with TACE plus sorafenib, but the difference was not statistically significant.…”

“…Secondly, two meta-analysis [ 7 , 19 ] demonstrated that apatinib combined with TACE provides better survival benefits for advanced-stage HCC patients than TACE monotherapy. Nevertheless, there is controversy around the efficacy of TACE in combination with apatinib or other TKIs [ 20 , 21 ]. Finally, the combination therapy with LEN-TACE has been heavily investigated recently and the efficacy is promising.…”

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study

“… 13–16 Moreover, compared with TACE combined with sorafenib, TACE with apatinib exhibited a comparable prognosis for advanced HCC. 17 , 18 Compared with c-TACE plus apatinib, DEB-TACE plus apatinib may increase the intratumor drug concentration and result in more sustained drug release, resulting in a better treatment response and long-term survival. Few studies are currently reporting differences in the treatment of DEB-TACE and c-TACE combined with apatinib for HCC patients, and there is no research developing and validating the predictive model for these patients.…”

Identification of Novel Genes and Associated Drugs in Cervical Cancer by Bioinformatics Methods

“…Pazopanib is a small-molecule inhibitor of a variety of protein tyrosine kinases, with potential antitumor activity [ 48 ]. Sorafenib works by stopping the progression of cancer and blocking the therapeutic replication of potentially malignant cells [ 49 ]. Nintedanib is a small-molecule kinase inhibitor that competitively inhibits both non-receptor tyrosine kinases and receptor tyrosine kinases, and these inhibitory effects increase fibroblast proliferation, migration, and transformation [ 50 ].…”